Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* instrumental and clinical diagnosis of every malignant neoplasm~* presence of pain with a neuropathic component in the opinion of the physician~* presence of pain \>=4(NRS)~* PS ECOG \<3~* written informed consent~Exclusion Criteria:~* serum creatinine \>2mg/ml or creatinine clearance \<40 ml/min~* mild or severe hepatic insufficiency~* iatrogenic neuropathy caused by chemotherapeutic agents~* previous allergic reactions to oxycodone and pregabalin~* pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
- B (Type: ACTIVE_COMPARATOR): pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops

Based on this trial design, predict the completion outcome and termination type (if applicable).